In this retrospective analysis, 30 patients with acute GVHD (aGVHD) and 32 patients with chronic GVHD (cGVHD) treated with extracorporeal photopheresis (ECP) performed by the COBE Spectra System were evaluated. After 3 months of ECP treatment, a CR and PR were observed in 9 (30%) and 6 (20%) patients with aGVHD and in 2 (6%) and 12 (38%) patients with cGVHD. In 16 (53%) patients with aGVHD and 9 (28%) with cGVHD ECP treatment was already stopped after 3 months. One (3%) patient with aGVHD and 7 (22%) patients with cGVHD received new additional immunosuppressive therapy started during the first 3 months of ECP treatment and were classified as 'nonresponder' with regard to ECP. Of these patients a PR was achieved in one patient with aGVHD and in three patients with cGVHD. Steroids could be tapered by X50 in 83% of patients with aGVHD and in 29% of patients with cGVHD after 3 months of ECP treatment. Patients with aGVHD achieving a CR or PR showed a significant improved OS after allo-SCT (P ¼ 0.019). ECP is associated with significant response rates and successful reduction of steroids in patients with GVHD.
INTRODUCTION
Acute GVHD (aGVHD) and chronic GVHD (cGVHD) are major causes of early TRM and late morbidity and mortality. Immunosuppressive agents such as steroids and calcineurin inhibitors provide the mainstay of treatment but are associated with an increased incidence of infections and several side effects.
Patients who are refractory to steroids are difficult to manage. A number of second-line therapies exist, including mycophenolate mofetil (MMF), mTOR inhibitors and monoclonal antibodies. 1 Extracorporeal photopheresis (ECP) is based on mononuclear cell (MNC) collection followed by ultraviolet (UVA) irradiation in presence of 8-methoxypsoralen (8-MOP) with reinfusion of the manipulated cells to the patient. This immune-modulatory therapy has the advantage of high tolerability with an absence of broad immunosuppression. The main proposed mechanism of action is induction of apoptosis of activated T cells. Ex vivo administered 8-MOP in the presence of UVA irradiation forms covalent bonds with DNA pyrimidine bases, intercalating into its structure and crosslinking the two DNA strands. 2 Circulating apoptotic cells are phagocytosed by APCs, leading to inhibition of proinflammatory cytokines and induction of regulatory T cells. [3] [4] [5] ECP may be performed employing two different techniques: an in-line photopheresis system (Therakos, UVAR XTS System, Ascot, Berkshire, UK) and the off-line method (COBE Spectra LRS System). 6 ECP is effective in the treatment of both steroid-refractory and -dependent aGVHD and cGVHD. [7] [8] [9] [10] [11] [12] Here, we report a retrospective analysis of 62 patients with aGVHD and cGVHD treated with ECP employing the COBE Spectra System. The aim was to assess possible factors influencing response to ECP and survival such as patients' clinical features, concomitant immunosuppressive treatment, and GVHD characteristics.
PATIENTS AND METHODS Patients
From August 1999 to August 2011, a total of 62 patients commenced ECP treatment for aGVHD (n ¼ 30) and cGVHD (n ¼ 32; classic GVHD: n ¼ 31; overlap syndrome: n ¼ 1). Patients were referred mostly from the transplant center of the University of Regensburg, Department of Hematology and Oncology, Germany. All patients provided informed consent to undergo treatment. Diagnosis of aGVHD and cGVHD and assessment of organ involvement were performed according to the criteria of Glucksberg and Thomas [13] [14] [15] [16] and the National Institute of Health (NIH) consensus criteria, respectively. 17 Nineteen patients with cGVHD developing GVHD before 2005 were reclassified according to the NIH criteria by chart review; 13 patients with cGVHD were prospectively classified. All ECP procedures were performed in the apheresis unit of the Department of Clinical Chemistry, University of Regensburg. Data were collected from the transplant center 0 s database and chart review (last follow-up data on the 21 May 2012).
ECP technique
The cell separator COBE Spectra LRS System (Lakewood, CO, USA) was used consisting of three steps: (1) collection of MNCs from the patient, (2) processing of MNC buffy coat and (3) reinfusion of MNCs to the patient. 8, 18, 19 The maximum final MNC volume collected was 90 mL (maximum procedure time: 180 min). The MNC volume was adjusted to a constant volume of 200 mL by addition of collected autologous plasma or sterile solution of sodium chloride 0.9%. The volume of 200 mL was interspersed with 2 mL 8-MOP (0.02 mg/mL) reaching a final concentration of the drug in the MNC solution of 200 ng/mL. The cellular product was then transferred into an extracorporeal UVA-permeable bag set (Cell Max GmbH, BELDICO SA/NV, Marche, Belgium). The UVA irradiation at 2 J/cm Since July 2011 the irradiator was replaced with Puva Combi Light (PCL, DELCOMp bvba, Leuven, Belgium). UVA irradiation at 1 J/cm 2 was performed at a wavelength of 365 nm over 1 min for each side of the bag reaching a total dose of 2 J/cm 2 . Anticoagulation consisted of acid-citrate-dextrose Formula A (ACD-A 500 mL, Acid citr. monohyd. 4.0 g, Baxter S. A., Lessines, Belgium) at a variable ratio of 1:11-1:13 according to the patient's characteristics.
Treatment schedule
The treatment schedule for aGVHD consisted of two (n ¼ 28) or three procedures per week (n ¼ 2) on consecutive days. Clinical improvement was based on individual investigator's assessment of one or two experienced physicians of the transplant unit. After clinical improvement defined as CR or PR of the GVHD, the ECP frequency was reduced to two procedures per week ( ¼ one cycle) every other week. In the presence of continuing clinical improvement including the possibility of steroid tapering the frequency of ECP was reduced to two consecutive procedures ( ¼ one cycle) once a month.
CGVHD treatment with ECP was initially performed with one cycle per week until improvement of the clinical manifestations followed by one cycle every other week for 3-4 weeks and subsequent treatment one cycle every month in the presence of remission of cGVHD.
ECP was stopped after either remission of GVHD remained stable or failure to improve after 4 weeks of treatment in aGVHD or failure to improve after 3 months in cGVHD. In the presence of progressive disease (PD) of GVHD the ECP was discontinued. In the presence of flare of GVHD symptoms during taper of steroids, the frequency of ECP sessions was increased. If more than two episodes of flares of symptoms of GVHD during steroid taper were observed, ECP was stopped as well.
Definition of ECP response
In aGVHD clinical response was evaluated after 4 weeks, 3 months, 6 months and at the end of ECP treatment. In cGVHD clinical response was assessed after 3 months, 6 months, 1 year, 2 years and at the end of ECP treatment.
A complete clinical response was defined as 'complete resolution' (CR) of all symptoms and signs of GVHD without starting new additional immunosuppressive therapy (IST) during ECP. A PR was defined as a 450% improvement of manifestations of GVHD compared with baseline but less than a CR.
No change (NC) was defined as stable organ involvement, despite tapering of other immunosuppressive agents by at least 50% of the dosage. Patients who developed progressive symptoms of GVHD and the inability to taper other medications were defined as PD. 9, 11 Patients receiving an additional IST started during the ECP treatment were classified as 'additional IST', as the impact of ECP on response could not be assessed directly in the latter situation. These patients were graded as 'nonresponder' with regard to ECP treatment.
For statistical analysis, all patients were divided into two groups: 'responder' (CR, PR) and 'nonresponder' (NC, PD, additional IST).
The indication for ECP was classified as steroid-dependent or steroid refractory. Steroid-dependent patients showed a response to steroids but repeated flare of symptoms during taper of steroids. Steroid refractory patients showed no response to steroids and had mostly PD despite treatment with steroids.
Statistical analysis
Descriptive data were summarized using median values, ranges and percentages for continuous variables. Categoric variables were summarized by the number and percentages in each category. OS since allo-SCT and since start of ECP treatment was analyzed using the Kaplan-Meier method. Log-rank test was used to test differences in survival curves. The Pearson's w 2 -test was used to compare categorical variables. Statistical analysis was undertaken using the IBM PASW Statistics 18.0 (IBM, New York, NY, USA). The competing risk analysis was performed using the R software (http://cran.R-project.org).
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RESULTS
Thirty patients with aGVHD and 32 patients with cGVHD were treated with ECP. In aGVHD the median follow-up was 23 months (range: 3-125 months), in cGVHD 54 months (range: 7-146).
Detailed patient characteristics including sex, age, diagnosis at transplant, GVHD characteristics, immunosuppressive medication, dosage of steroids, indication for ECP, details of the ECP treatment and donor type are provided in Tables 1 and 2 . Response to ECP after 4 weeks in aGVHD and after 3 months in aGVHD and cGVHD In aGVHD 11 (37%) patients achieved a CR or PR after 4 weeks of ECP treatment (CR in 4 (13%) and PR in 8 (27%) patients). In 6 (20%) patients a PD was observed. Eight (27%) patients received additional IST during the first 4 weeks of ECP treatment interfering with evaluation of response. In three patients ECP was already terminated at that time. Reasons for the termination in two patients were a progressive GVHD and in one patient an infection of the indwelling catheter after achieving a PR. Patients considered as 'responder' showed a statistically significant better OS than patients of the 'nonresponder' group after 4 weeks of ECP treatment, both according cumulative survival after start of ECP (P ¼ 0.011) and OS after allo-SCT (P ¼ 0.019). After 3 months of therapy a CR and a PR was observed in 9 (30%) and 6 (20%) patients with aGVHD (Table 3 ). In 16 (53%) patients the ECP treatment was already terminated at 3 months because of PD (n ¼ 5), CR (n ¼ 1), PR (n ¼ 3), additional IST (n ¼ 6) or because of infectious complications (n ¼ 1). In summary, 15 (50%) patients with aGVHD were 'responder' after 3 months of ECP treatment.
After 3 months of treatment a CR and a PR was observed in 2 (6%) and 12 (38%) patient(s) with cGVHD (Table 3 ). Nine (28%) patients already terminated the ECP treatment. Reasons for the termination were in one patient the achievement of a CR (n ¼ 1), a PR (n ¼ 3), a PD (n ¼ 1), additional IST (n ¼ 3) and infectious complication (n ¼ 1). In summary, 14 (44%) patients with cGVHD were 'responder' after 3 months of ECP treatment.
Response after 6 months of ECP procedures After 6 months of ECP treatment a CR and PR were observed in 8 (27%) and 5 (17%) patients with aGVHD. In summary, 13 of 30 (43%) were considered as 'responders'.
In 20 patients the ECP treatment was stopped at 6 months. Of these, three patients achieved a CR and four achieved a PR (Table 4) . In cGVHD a response after 6 months was achieved in 16 (50%) patients (CR: n ¼ 4 (12.5%) and PR: n ¼ 12 (37.5%)). In 15 patients (47%) the ECP treatment has been stopped already. Of these patients one patient achieved a CR and four achieved a PR (Table 4 ).
Response to ECP at the end of ECP treatment A CR and PR were observed in 6 (20%) and 5 (17%) patients with aGVHD at the end of ECP treatment. Five patients (17%) showed a PD. In one patient NC was observed in symptoms of aGVHD. Thirteen (43%) patients received additional IST during the ECP treatment interfering with evaluation of response. These patients were classified as 'additional IST' and graded as 'nonresponder' with regard to ECP treatment. In aGVHD reasons for the additional IST were the following: 5 (17%) patients with no change of GVHD and 8 (27%) patients with progressive GVHD. Within the group of patients receiving additional new IST 3 (10%) patients achieved a CR and 6 (20%) a PR.
In cGVHD a response was achieved in 14 (44%) patients (CR: n ¼ 6 (19%) and PR: n ¼ 8 (25%)). Only 1 (3%) patient showed a PD. In 4 (12.5%) patients no NC was observed in symptoms of cGVHD. Thirteen (41%) patients received additional IST during the first 3 months of ECP treatment interfering with evaluation of response ('additional IST'). In cGVHD reasons for the additional IST were the following: 6 (19%) patients with NC of GVHD, 6 (19%) patients with progressive GVHD and 1 (3%) patient with toxicity to prior IST. In 7 (22%) patients a PR was achieved with additional IST during ECP.
There were different combinations of new IST in the group 'additional IST' in aGVHD and cGVHD. The most frequently applied new agents for IST during ECP in aGVHD were tacrolimus, MMF, ECP is associated with significant response rates AH Hautmann et al everolimus and etanercept, and in cGVHD MMF, everolimus and rituximab. If the patient developed progressive GVHD symptoms or o3 flares of symptoms during taper of steroids (after an initial partial or complete response of GVHD symptoms) or no change of GHVD symptoms the IST was intensified in some cases. The decision for the individual immunosuppressive medication was made on the basis of toxicity profile of the medication before use of immunosuppressive agents and comorbidities of the patient's characteristics.
Association to response
Only patients with steroid-dependent aGVHD showed a response to ECP. Twelve patients with steroid-dependent cGVHD were responder to ECP, whereas only two patients with steroid refractory cGVHD showed a response. The association between response and indication for ECP (steroid-dependent versus steroid-refractory GVHD) was statistically significant (P ¼ 0.001 in aGVHD and P ¼ 0.007 in cGVHD). 
ECP is associated with significant response rates AH Hautmann et al
There was no other association with ECP response. Although no statistically significant difference between the response rates of the different organ involvements was detectable, patients with aGVHD with skin involvement had by trend a better response rate compared with patients with gut involvement. In cGVHD, patients with cutaneous involvement seem to have better response rates to ECP treatment (Tables 3 and 4) .
Reduction of immunosuppression after 3 and 6 months of treatment The dosage of steroids at the start of ECP is shown in Table 5 . Indication for tapering steroids and other immunosuppressive medication was an achievement of PR or CR of GVHD symptoms. Normally steroids were tapered first. Exceptions were the need to taper other immunosuppressive medication first because of toxicity and/or comorbidities of the patient.
In 10 of 12 (83%) patients with aGVHD and in 5 of 17 (29%) patients with cGVHD, who continued ECP treatment at 3 months, steroids could be tapered by X50%. In 16 (53%) patients with aGVHD ECP treatment was already stopped at 3 months; of 2 patients data of the steroid dosage at 3 months was missing. Nine (28%) patients with cGVHD had already stopped ECP treatment at 3 months; of three patients data of the steroid dosage at 3 months was missing. Three patients with cGVHD did not receive any steroids.
The median dosage of steroids at 3 months of ECP procedures was 0.3 mg/kg body weight in patients with aGVHD and 0.2 mg/kg body weight in patients with cGVHD (Table 5 ). At 6 months of ECP treatment 5 (16%) of the patients with cGVHD received no steroids any more. In 2 (7%) and in 4 (12.5%) patients with aGVHD and cGVHD the dosage of prednisolone was p5 mg/day at 6 months of ECP treatment.
In patients with aGVHD a statistically significant association between the response rate and taper of steroids could be shown (P ¼ 0.017), resulting in a significant improved cumulative survival of patients after start of ECP (P ¼ 0.018).
Intensity of concomitant IST was reassessed at 3 months, at 6 months and at the end of ECP treatment. After 3 months of ECP treatment in 2 of 12 (17%) patients with aGVHD a reduction of one immunosuppressive medication was possible, in 2 (17%) a reduction of two medications was feasible. In 5 (42%) with aGVHD no reduction of the IST was observed. In 2 (17%) patients the IST had to be increased with one additional drug. In 16 patients ECP treatment was already terminated; of 2 patient data about the concomitant IST was not available.
After 3 months of ECP treatment in 8 of 20 (40%) patients with cGVHD a reduction of one immunosuppressive drug was feasible.
In 11 of 20 (55%) with cGVHD no reduction of the IST was observed. In one patient (5%) the IST had to be increased with one additional drug. At 3 months in 9 patients ECP treatment was already terminated; of 3 patients data about the concomitant IST at 3 months was missing (Table 5 ).
Survival and TRM At last follow-up, 13 (43%) patients with aGVHD died due to TRM and 8 (27%) due to relapse. In total, 21 (70%) of all patients with aGVHD have died at last follow-up. In patients with aGVHD 5 (17%) died of an infection, 7 (23%) died of progressive GVHD and 1 had another cause of death.
In cGVHD 11 (34%) patients died due to TRM and 3 (9%) patients due to relapse. In total, 14 (44%) patients have died at last follow-up. In patients with cGVHD 6 (19%) died of an infection and 2 (6%) of progressive GVHD. Three patients (9%) had other causes of death (for example, myocardial infarction, pulmonary embolism).
In the competing risk analysis, cumulative incidence curves for 'responder' and 'nonresponder' are both not significantly different for death due to TRM (P ¼ 0.067) and due to relapse (P ¼ 0.87) in aGVHD ( Figure 1 ). In the competing risk analysis in patients with cGVHD, cumulative incidence curves for 'responder' and 'nonresponder' are both significantly different for death due to TRM (P ¼ 0.04), and for relapse (P ¼ 0.04) (Figure 2) .
Patients with aGVHD responding to ECP had a significant improved OS (median OS is not reached at last follow-up, range: 5-125 months) and cumulative survival after start of ECP compared with patients failing to achieve at least partial response (median OS after allo-SCT: 9 months, range: 3-47) (P ¼ 0.019; P ¼ 0.018) (Figure 3) . Supplementary information according survival data (Supplementary Table 1 ) is available at BMT's website. 
Details of the MNC buffy coat
The leukocyte count, the hemoglobin concentration, the hematocrit and the platelet count were measured in the MNC buffy coat. The median leukocyte count was 20.8/nL (range 4.2-55.1/nL), the median hemoglobin concentration was 0.9 g/dL (range 0.1-1.7 g/dL), the median platelet count was 458/nL (range 77-1101/nL).
DISCUSSION
ECP has been used frequently in steroid-dependent and steroid refractory aGVHD and even more often in cGVHD patients during the past years. Overall, complete and partial resolution of cutaneous manifestations in aGVHD were observed in a median of 75% (range: 50-100%), of hepatic involvement in a median of 47% (range: 0-100%) and of gastrointestinal manifestations in a median of 58% (range: 0-100%) of patients. 6, 8, 9, 11, 12, [22] [23] [24] [25] [26] [27] [28] In this retrospective analysis the response rate in aGVHD was 50% after 3 months. In our analysis patients receiving additional new IST during ECP were classified as 'nonresponders', which might be the reason for the lower response rates in aGVHD in our series of patients compared with published results reflecting the limitations of a retrospective analysis of the daily practice. Nevertheless, a significant proportion of patients receiving additional new IST responded to treatment but the relationship to ECP remains unclear.
Moreover, ECP procedures were started after failure of secondline therapy in 23 (66%) patients with aGVHD within our cohort while the majority of published results on ECP reported on results in second-line therapy.
Overall, complete and partial resolutions of manifestations in cGVHD were reported in a median of about 65% (range: 61-79%). 7, 10, 12, 29, 30 In several retrospective analyses with a limited number of patients consistently high CR in up to 70% of patients with cutaneous manifestations and significant improvement of oral or ophthalmic involvement are reported. 1, 10 Couriel et al.
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reported after 6 months of ECP treatment a total of 27 (69%) of 39 patients with a sustained response to ECP (CR 10 patients (4%) and PR 23 patients (59%). 10 In this analysis, the response rate in patients with cGVHD was 44% after 3 months of ECP treatment. Again, patients receiving additional IST initiated during ECP were classified as 'nonresponder', which might be the reason for the lower response rates in cGVHD.
The reported steroid-sparing effect of ECP could be confirmed within our cohort with 83% of patients with aGVHD and 29% with cGVHD, achieving at least a dose reduction of 50% of baseline dose after 3 months of ECP treatment. 6, 9, [29] [30] [31] Perotti et al. showed that the ability to decrease the corticosteroid dose 30 days after the start of ECP was associated with significantly decreased mortality, confirming the importance of corticosteroidsparing in GVHD.
In our analysis, we found a statistically significant better response rate in patients with steroid-dependent GVHD than in patients with steroid refractory GVHD, both in aGVHD and cGVHD. Within our cohort of patients we were not able to demonstrate a significant association between severity and organ distribution of aGVHD and cGVHD and response to ECP. However, although not significant, a trend toward better response rates in patients with cutaneous involvement than gastrointestinal involvement of aGVHD was recognized, which is in line with published results. 11, 22 In cGVHD, lung involvement had the worst response rates and involvement of skin had better response rates, which is described in literature as well. Within our analysis, the time between aGVHD and cGVHD onset and first ECP treatment did not influence the ECP response. Several transplant centers apply an 'early treatment' policy due to the favorable risk profile of ECP compared with other treatment options of GVHD. 8, 9 Within our analysis, ECP was often applied as third-or fourth-line therapy explaining in part the reduced response rate as some GVHD manifestations result in irreversible organ damage through the course of GVHD. Therefore, ECP should be considered more often as a second-line therapy before irreversible changes manifest.
Nevertheless, our results demonstrate that a later start of ECP treatment might be successful in some patients as well and should be also considered in patients who have failed multiple therapies and in whom treatment options are often limited. 32 Of clinical relevance is the observation that patients with aGVHD responding to ECP have a significant improved OS compared with 'nonresponder', which is in line with published results. 6, 9 In our analysis a significant association between the response rate in aGVHD after 4 weeks of ECP treatment and the OS could be shown. These findings suggest a good prognosis of patients with aGVHD obtaining a CR or PR after 4 weeks of ECP procedures.
In conclusion, ECP is tolerated well and has an excellent safety profile in adults and children. The treatment is effective in aGVHD and cGVHD and is associated with significant steroid-sparing activity and improves survival in aGVHD.
